Results 21 to 30 of about 74,841 (314)
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis
Toxins, 2022 Botulinum toxin (BT) is an effective treatment for spasticity symptoms in multiple sclerosis (MS). Despite its wide use in clinical practices, only few studies have explored long-term persistence.
Federica Novarella +13 more
doaj +1 more source
Indian Journal of Dermatology, 2010 Botulinum toxin, one of the most poisonous biological substances known, is a neurotoxin produced by the bacterium Clostridium botulinum. C. botulinum elaborates eight antigenically distinguishable exotoxins (A, B, C(1), C(2), D, E, F and G). All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal ...
Nigam P, Nigam Anjana
openaire +3 more sources
, 2021 The physician and patient come into close contact during botulinum toxin treatments, increasing the chances of COVID-19 infection. Therefore, it is essential to use an effective injection method that can prevent infection with SARS-CoV-2 virus.
Altavista, Maria Concetta +4 more
core +1 more source
Patient-Reported Side Effects of Intradetrusor Botulinum Toxin Type A for Idiopathic Overactive Bladder Syndrome [PDF]
, 2010 Objective: The aim of the study was a prospective assessment of patient-reported side effects in an open-label study after intradetrusor botulinum toxin injections for idiopathic overactive bladder (OAB). Patients and Methods: Botulinum toxin A injection
Mayer, Margit E. +15 more
core +1 more source
Health and Society, 2022 Botulinum neurotoxins (BoNT) are toxins produced by bacteria of the genus Clostridium botulinum and are considered as the most potent toxins nowadays. Firstly, known as a food poison, later explored as a biological weapon and currently considered a great therapeutic resource. Seven different BoNT serotypes (A-G) have already been identified. Among them,
Bruna Luiza Ribeiro de Almeida +2 more
openaire +2 more sources
Release of vasopressin from isolated permeabilized neurosecretory nerve terminals is blocked by the light chain of botulinum A toxin [PDF]
, 1990 The intracellular action on exocytosis of botulinim A toxin and constituent chains was studied using permeabilized isolated nerve endings from the rat neural lobe. The release of the neuropeptide vasopressin was measured by radioimmunoassay.
Weller, U. +4 more
core +1 more source
Botulinum Toxin as Preventive Treatment for Migraine: A Randomized Double-Blind Study [PDF]
, 2009 Aim: To determine if botulinum toxin type A (BoNT-A) injections can reduce the frequency and severity of migraines. Methods: Patients (n = 127) were randomized to receive placebo or two doses of BoNT-A (Dysport (R)). The primary endpoint was reduction in
Toelle, Thomas +13 more
core +1 more source
Botulinum toxin a in the treatment of blepharospasm - A 10-year experience [PDF]
, 2005 To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clinicas ...
Goncalves, LR +7 more
core +1 more source
On Botulinum Neurotoxin Variability [PDF]
mBio, 2015 ABSTRACT The rapidly growing number of botulinum neurotoxin sequences poses the problem of the possible evolutionary significance of the variability of these superpotent neurotoxins for toxin-producing Clostridium species. To progress in the understanding of this remarkable phenomenon, we suggest that researchers should (i) abandon an anthropocentric ...
MONTECUCCO, CESARE +1 more
openaire +4 more sources
The light chain but not the heavy chain of botulinum A toxin inhibits exocytosis from permeabilized adrenal chromaffin cells [PDF]
, 1989 The heavy and light chains of botulinum A toxin were separated by anion exchange chromatography. Their intracellular actions were studied using bovine adrenal chromaffin cells permeabilized with streptolysin O.
M. Gratzl +10 more
core +1 more source